Considered immune if 2 documented doses of vaccine or positive serology
Contraindicated if plan to start therapy in < 4 weeks. Contraindicated in pregnancy.
When rapid protection is required, a minimum interval of 4 weeks between the 2 doses is acceptable.
Contraindicated.
Contraindicated if plan to start therapy in < 4 weeks. Contraindicated in pregnancy.
When rapid protection is required, a minimum interval of 4 weeks between the 2 doses is acceptable.
Contraindicated.
Stelara®/Janssen/BioAdvance® (2009)
Monoclonal antibody interleukin (IL)-12/23 inhibitor
Targets an overactive immune system by blocking two receptors called IL-12 and IL-23. By blocking these receptors, cells are slowed down, which reduces inflammation.
Monoclonal antibody integrin receptor blocker
Skyrizi®/AbbVie/AbbVie Care (2019)
Monoclonal antibody interleukin (IL)-23 inhibitor
Targets IL-23 protein receptor, which is one of the proteins responsible for inflammation. Blocking this receptor contributes to reducing inflammation.
Rinvoq/Abbvie/Abbvie Care (2023)
JAK Inhibitor
JAKs are intracellular enzymes that activate the body’s immune response causing inflammation. JAK inhibitors block this pathway. Works by attaching to the JAK enzyme to lower its activity and to decrease inflammation in the body.